Outcry over REACH from beyond the EU
This article was originally published in Clinica
The contents of the EU's proposed chemicals Regulation, REACH, has caused outrage beyond the EU's borders. Both the authorisation and registration rules have been heavily criticised by a coalition of states, including the US, Brazil and India, who are particularly concerned about the impact of REACH, particularly on SMEs - and especially on manufacturers from developing countries. The coalition, which also includes Japan, Australia, Korea, Malaysia, Singapore, Thailand, Mexico, South Africa, Israel and Chile, is calling on the EU to "use the second reading in Parliament to address the problematic aspects of the proposal".
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.